Skip to content
10-Q

Quarterly Report

Aerie Pharmaceuticals, Inc.

0001337553-22-000024

← back to feed
Filed
May 6, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · Apr 29, 2022 48.62M sh
Shares Diluted Q1 2022 · Mar 31, 2022 47.52M sh
Shares Diluted Q1 2022 · Mar 31, 2021 46.11M sh
Capex Q1 2022 · Mar 31, 2022 $1.6M
Capex Q1 2022 · Mar 31, 2021 $772K
Operating Cash Flow Q1 2022 · Mar 31, 2022 $61.91M
Operating Cash Flow Q1 2022 · Mar 31, 2021 −$30.05M
Short Term Investments Q1 2022 · Mar 31, 2022 $138.81M
Short Term Investments Q1 2022 · Dec 31, 2021 $102.61M
Cash And Equivalents Q1 2022 · Mar 31, 2022 $56.44M
Cash And Equivalents Q1 2022 · Dec 31, 2021 $37.19M
Stockholders Equity Q1 2022 · Mar 31, 2022 −$125.71M
Stockholders Equity Q1 2022 · Dec 31, 2021 −$17.33M
Stockholders Equity Q1 2022 · Mar 31, 2021 −$10.37M
Stockholders Equity Q1 2022 · Dec 31, 2020 $23.97M
Current Liabilities Q1 2022 · Mar 31, 2022 $115.29M
Current Liabilities Q1 2022 · Dec 31, 2021 $124.99M
Total Liabilities Q1 2022 · Mar 31, 2022 $521.26M
Total Liabilities Q1 2022 · Dec 31, 2021 $448.72M
Current Assets Q1 2022 · Mar 31, 2022 $316.97M
Current Assets Q1 2022 · Dec 31, 2021 $355.65M
Total Assets Q1 2022 · Mar 31, 2022 $395.55M
Total Assets Q1 2022 · Dec 31, 2021 $431.39M
Eps Diluted Q1 2022 · Mar 31, 2022 −$0.76
Eps Diluted Q1 2022 · Mar 31, 2021 −$0.91
Eps Basic Q1 2022 · Mar 31, 2022 −$0.76
Eps Basic Q1 2022 · Mar 31, 2021 −$0.91
Sga Expense Q1 2022 · Mar 31, 2022 $31.52M
Sga Expense Q1 2022 · Mar 31, 2021 $32.6M
Rd Expense Q1 2022 · Mar 31, 2022 $25.17M
Rd Expense Q1 2022 · Mar 31, 2021 $17.89M
Net Income Q1 2022 · Mar 31, 2022 −$35.89M
Net Income Q1 2022 · Mar 31, 2021 −$41.96M
Operating Income Q1 2022 · Mar 31, 2022 −$33.64M
Operating Income Q1 2022 · Mar 31, 2021 −$34.22M
Cost Of Revenue Q1 2022 · Mar 31, 2022 $6.78M
Cost Of Revenue Q1 2022 · Mar 31, 2021 $6.7M
Revenue Q1 2022 · Mar 31, 2022 $29.84M
Revenue Q1 2022 · Mar 31, 2021 $22.97M